Mannitol Eutectic Cyclobenzaprine for Early Fibromyalgia Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibromyalgia, such as the three FDA-approved drugs, have significant tolerability and side effect issues, particularly affecting weight, blood pressure, and sexual functioning, limiting their use and leaving an unmet need for effective management of fibromyalgia symptoms.
Innovation Solution
Administering cyclobenzaprine HCl in the form of a mannitol eutectic, such as 75% cyclobenzaprine HCl and 25% β-mannitol, via transmucosal routes like sublingual administration, with or without a basifying agent, to achieve early onset reductions in pain, sleep disturbance, fatigue, and improved sleep quality, while minimizing side effects on weight, blood pressure, and sexual functioning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current FDA-approved drugs are used to treat fibromyalgia, then pain relief is achieved, but significant side effects occur affecting weight, blood pressure, and sexual functioning
Solution Approach 1:
The patent changes the administration route parameter from oral to transmucosal (sublingual/buccal), which alters the pharmacokinetic profile and reduces first-pass metabolism, thereby achieving effective pain relief while minimizing the harmful side effects on weight, blood pressure, and sexual functioning that are associated with conventional oral medications
Solution Approach 2:
The patent uses a mannitol eutectic formulation as an intermediary carrier system that enables controlled release and enhanced permeation of cyclobenzaprine through the mucosal membrane, allowing effective drug delivery while reducing the accumulation of harmful metabolites that cause the observed side effects
2Speed
If transmucosal administration of cyclobenzaprine HCl is used, then early onset pain reduction is achieved, but the formulation complexity increases
Solution Approach 1:
The patent utilizes the phase transition properties of the mannitol eutectic system, where the eutectic mixture creates a liquid membrane that facilitates rapid drug permeation through the mucosa, achieving fast onset of action while the eutectic structure itself provides the formulation framework
Solution Approach 2:
The patent employs a composite formulation combining cyclobenzaprine HCl with mannitol in specific eutectic ratios (75:25 or 65:35 by weight), where the composite material properties enable enhanced permeation and rapid absorption while maintaining formulation stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cyclobenzaprine HCl provides favorable tolerability and side effect profiles, achieving significant reductions in widespread pain, sleep disturbance, fatigue, and improved sleep quality, while avoiding clinically meaningful changes in weight, blood pressure, and sexual functioning.
Implementation Method 1
the cyclobenzaprine HCl being in the form of a mannitol eutectic selected from the group consisting of a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic, a 65%±2% by weight cyclobenzaprine HCl and 35%±2% by weight δ-mannitol eutectic
Implementation Method 2
administering to a subject in need thereof 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration
Data Source
AI summary
The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic) and the one or more dosage units further comprise a basifying agent.